If your company has used Cetero Research's Houston facility to conduct bioanalytical studies between April 1, 2005 and June 15, 2010, your marketing applications may need to be repeated or confirmed. By now, you should have received a letter from FDA asking that new bioequivalence studies be conducted, or if there is supporting stability of the analyte throughout the entire frozen storage period, that samples from the original BE studies be re-assayed.
The week, FDA further clarified their requirements regarding studies conducted at Cetero during the aforementioned time frame as follows:
ProPharma Group, a globally recognized regulatory and scientific consulting firm headquartered in Washington DC, has experience helping pharma companies in these matters. We were, in fact, a key player in remediating the similar MDS Pharma Services crisis at their Montreal facility in 2007, helping our clients prevail with minimal disruption to their organizations and supply chains.
If you are in need of our assistance, please do not hesitate to contact Jeff Antos (202.280.0815) immediately.
March 27, 2023
ProPharma applauds the myriad of recent, positive developments for clinical trials in the UK, representing the biggest overhaul in UK clinical trials in two decades. Lord O’Shaughnessy Clinical Trial...
October 18, 2018
Sponsors may transfer any or all of their many tasks and obligations relating to clinical trials to Contract Research Organizations (CROs). This ability to delegate through a Transfer of Regulatory...
July 17, 2023
Decentralized clinical trials (DCTs) have emerged as a transformative approach in clinical research, offering unique benefits that challenge the traditional models. However, deciding whether to...